EP1542644A1 - Medikament-dosimeter-kombipackung - Google Patents
Medikament-dosimeter-kombipackungInfo
- Publication number
- EP1542644A1 EP1542644A1 EP03773458A EP03773458A EP1542644A1 EP 1542644 A1 EP1542644 A1 EP 1542644A1 EP 03773458 A EP03773458 A EP 03773458A EP 03773458 A EP03773458 A EP 03773458A EP 1542644 A1 EP1542644 A1 EP 1542644A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- drug
- patient
- pack according
- combination pack
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/008—Electronic counters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0076—Medicament distribution means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/06—Packaging for specific medical equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
Definitions
- the present invention relates to a system for the individual dosage of a pharmaceutical substance, corresponding to the individual phathological, physiological or genetic properties ('fingerprint') of a patient corresponding to the disease state.
- the system consists of two components, the drug, which is taken or administered in variable individual doses, and a miniaturized display system that extracts and reads information from the patient's blood, saliva or other body fluids and tissues so that it is legible the patient or the treating doctor can immediately see the optimal dose to be taken or administered.
- the present invention relates to a medicament-dosimeter combination pack, which is packaged in a. an individually metered drug, and b. contains a diagnostic display system for an endogenous substance, regulatory mechanism or gene or indication system, relevant for the effect, side effect, interaction, metabolism, absorption, distribution, metabolism and elimination of the drug to be administered.
- the system according to the invention is particularly suitable for the individual dosage of a pharmaceutical substance, corresponding to the individual pathological and physiological or genetic properties ('fingerprint') of a patient.
- the system consists of two components, the drug, which is taken or administered in variable individual doses, and a miniaturized display system that extracts and reads information from the patient's blood, saliva or other body fluids and tissues so that it is legible the patient or the treating doctor can immediately see the optimal dose to be taken or administered. In special cases it can also be seen whether a therapeutic effect can be achieved at all by taking a certain medication (responder / non-responder definition).
- the display system will consist of a paper or plastic stick, at the end of which there is a reactive zone which is brought into contact with the body fluid.
- This can either be a paper strip soaked with a reaction mixture, or a depression (wave), or a vessel with indicator solution or reaction solution in which the body fluid and a chemical fluid are mixed.
- the result of the reaction is displayed in the simplest case as a color change and as such can signal the patient or doctor an area or an exclusion limit, which the patient can then use to decide on the amount of medication to be taken.
- the test system can also be based on a quantitative chemical reaction, the result of which can not only be assessed with the naked eye, but can also be quantitatively recorded and read as a defined value after inserting the test stick or the test wave into an appropriate analytical device ('indicator') ,
- the analytical device in turn can be connected to a database in which historical data of the patient are already stored and can thus be used for decision making.
- a test system can also consist of a chip which is coated with one or more reactive substances and, after reacting with the body fluid applied, delivers one or more measurable results and suggests, permits, or excludes doses.
- the test system and the dosage form can be networked with one another in such a way that, by bringing the chip together with a corresponding chip on or in the dosage form, the latter, without the patient's or doctor's intervention, names the optimal dose of the drug substance based on the information made available to it or releases.
- Examples are a cassette which releases a certain amount of capsules or tablets according to the information read, a programmed drop or cream dispenser, a subcutaneous injection e.g. with a 'pen injector', which injects a precisely defined, but variable amount of drug depending on the individual information under the skin, or a variable nebulizer, which nebulizes the amount of substance corresponding to the information, which the patient then inhales.
- Possible embodiments of the invention include the following combinations.
- the medicament-dosimeter combination pack has two separate compartments in which the medicinal substance is accommodated in a specific dosage form in one and the corresponding number of test strips in the other. In this case, it is up to the patient or doctor to use the display system before administering an appropriate dose.
- the drug-dosimeter combination pack can, however, also be constructed in such a way that the patient or doctor must first remove the indicator strip, for example pull it out or cancel it, before the drug can be removed for administration.
- the drug-dosimeter combination pack is designed so that the patient or doctor must carry out the test with the display system before the drug is released in a specific dose resulting from the test. This can best be achieved with a display system that works on a chip basis, since quantitative information can be transferred directly to a mechanical system, so that, for example, a pill wheel with a rotating mechanism can only be opened by a defined number of revolutions, which then corresponds to a certain dosage of the drug contained in the tablets or capsules.
- the object according to the invention is designed as a container filled with small tablets, pellets or micropellets, which releases a defined amount / number of solids.
- the container contains a liquid substance, a defined volume for oral, sublingual or topical application being delivered in each case.
- Another example would be an injector which, based on the information transferred from the chip, only a certain volume of drug e.g. injected under the skin, or an aerosol device, which, based on the information of the chip inserted into the device, nebulizes a certain volume, which contains a defined amount of drug, which the patient then inhales.
- a certain volume of drug e.g. injected under the skin
- an aerosol device which, based on the information of the chip inserted into the device, nebulizes a certain volume, which contains a defined amount of drug, which the patient then inhales.
- the transmission should be wireless and in real time (eg Bluetooth technology).
- HER2 In a patient's tumor tissue, the expression of HER2 is measured before the start of breast cancer therapy with antibodies against HER2. Therapy is only started when HER2 is overexpressed.
- Antioestrogen therapy e.g. with tamoxifen
- other tumor therapies e.g. with tamoxifen
- the patient carries out an estrogen receptor expression test using the display system provided.
- An individual dosage is calculated from the measured number of receptors.
- a tumor marker is determined (e.g. M2-PK, CEA. MUC-1, etc), which indicates the suppression or spread of the metastasis of the tumor. This means that the optimal dosage is always made available over the course of long-term treatment.
- the creatine kinase (CK) or elastase from the patient's serum is measured before taking the lipid-lowering agent.
- the dosage is lowered or the medication is discontinued if increased rhabdomyolysis (enzymatic muscle breakdown) can be calculated from the measured concentration of CK or elastase.
- a receptor expression test is carried out, whereby a change in the number of receptors (up / down regulation) is recognized and the dosage can be adjusted accordingly.
- Antidepressants or other Cyt. P450 inhibiting or stimulating drugs
- the enzyme cytochrome P450 responsible for the metabolism can be inhibited or particularly active when taking antidepressants. This can lead to inhibition of the metabolism of the antidepressants taken, but also of other medicinal substances. This can result in dangerously high plasma levels. On the other hand, a very strong metabolism prevents the build-up of an effective blood level.
- a patient's cytochrome P450 is characterized with a gene expression chip either directly or indirectly via metabolic conversion of a corresponding substrate. Based on the result, the patient is classified as a slow / fast metabolizer and the dose of the antidepressant is adjusted accordingly.
- non-responder which is often subject to substantial side effects of pre- neherein (nonsensical treatment) before an ineffective to preserve.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10245508 | 2002-09-27 | ||
DE10245508A DE10245508A1 (de) | 2002-09-27 | 2002-09-27 | Medikament-Dosimeter-Kombipackung |
PCT/DE2003/003186 WO2004030604A1 (de) | 2002-09-27 | 2003-09-24 | Medikament-dosimeter-kombipackung |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1542644A1 true EP1542644A1 (de) | 2005-06-22 |
EP1542644B1 EP1542644B1 (de) | 2007-12-05 |
Family
ID=31984252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03773458A Expired - Fee Related EP1542644B1 (de) | 2002-09-27 | 2003-09-24 | Medikament-dosimeter-kombipackung |
Country Status (7)
Country | Link |
---|---|
US (3) | US20060062733A1 (de) |
EP (1) | EP1542644B1 (de) |
JP (1) | JP2006500178A (de) |
AU (1) | AU2003281921A1 (de) |
DE (3) | DE10245508A1 (de) |
TN (1) | TNSN05091A1 (de) |
WO (1) | WO2004030604A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4718543B2 (ja) | 2004-04-30 | 2011-07-06 | ベクトン・ディキンソン・アンド・カンパニー | 医療投薬処方を管理するための装置及び方法 |
DE102007051757A1 (de) | 2007-10-30 | 2009-05-07 | Ecker, Felix, Prof. Dr. | Verfahren zur automatischen Herstellung von patientenindividuell dosierten pharmazeutischen Zubereitungen |
PT2886126T (pt) | 2013-12-23 | 2017-09-13 | Exchange Imaging Tech Gmbh | Nanopartícula conjugada a péptidos de ligação a cd44 |
KR20190015345A (ko) * | 2016-05-25 | 2019-02-13 | 에프. 호프만-라 로슈 아게 | 용량 용법 디자인에 관한 재료 및 방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4935346A (en) * | 1986-08-13 | 1990-06-19 | Lifescan, Inc. | Minimum procedure system for the determination of analytes |
US6309822B1 (en) * | 1989-06-07 | 2001-10-30 | Affymetrix, Inc. | Method for comparing copy number of nucleic acid sequences |
US7970620B2 (en) * | 1992-11-17 | 2011-06-28 | Health Hero Network, Inc. | Multi-user remote health monitoring system with biometrics support |
US5536249A (en) * | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
FR2721521B1 (fr) * | 1994-06-27 | 1996-12-13 | Commissariat Energie Atomique | Dispositif microdoseur pulvérisateur automatique de médicament et ensemble doseur intelligent utilisant ce dispositif. |
US5665065A (en) * | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
US6287805B1 (en) * | 1998-03-20 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules of the protein-coupled heptahelical receptor superfamily and uses therefor |
US6660750B2 (en) * | 2000-02-15 | 2003-12-09 | University Of Iowa Research Foundation | Flavopiridol methods and compositions for HIV therapy |
US6625518B2 (en) * | 2000-06-22 | 2003-09-23 | Csem Centre Suisse D'electronique Et De Microtechnique Sa | Method supporting administration of a prescribed drug and implementing said method |
US6383789B1 (en) * | 2001-03-22 | 2002-05-07 | Pe Corporation (Ny) | Isolated human UDP-glycosyltransferase, nucleic acid molecules encoding human UDP-glycosyltransferase, and uses thereof |
GB0127989D0 (en) * | 2001-11-22 | 2002-01-16 | Glaxo Group Ltd | Medicament dispensing system |
-
2002
- 2002-09-27 DE DE10245508A patent/DE10245508A1/de not_active Withdrawn
-
2003
- 2003-09-24 EP EP03773458A patent/EP1542644B1/de not_active Expired - Fee Related
- 2003-09-24 AU AU2003281921A patent/AU2003281921A1/en not_active Abandoned
- 2003-09-24 WO PCT/DE2003/003186 patent/WO2004030604A1/de active IP Right Grant
- 2003-09-24 DE DE50308742T patent/DE50308742D1/de not_active Expired - Lifetime
- 2003-09-24 US US10/528,783 patent/US20060062733A1/en not_active Abandoned
- 2003-09-24 JP JP2004540506A patent/JP2006500178A/ja active Pending
- 2003-09-24 DE DE10393889T patent/DE10393889D2/de not_active Expired - Fee Related
-
2005
- 2005-03-25 TN TNP2005000091A patent/TNSN05091A1/en unknown
-
2010
- 2010-07-05 US US12/830,367 patent/US20100332029A1/en not_active Abandoned
-
2011
- 2011-09-28 US US13/247,078 patent/US20120104039A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2004030604A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20100332029A1 (en) | 2010-12-30 |
EP1542644B1 (de) | 2007-12-05 |
US20120104039A1 (en) | 2012-05-03 |
TNSN05091A1 (en) | 2007-05-14 |
AU2003281921A1 (en) | 2004-04-23 |
US20060062733A1 (en) | 2006-03-23 |
JP2006500178A (ja) | 2006-01-05 |
DE10393889D2 (de) | 2005-08-25 |
WO2004030604A1 (de) | 2004-04-15 |
DE50308742D1 (de) | 2008-01-17 |
DE10245508A1 (de) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69530845T2 (de) | Gerät zur intrapulmonaren Arzneiverabreichung in therapeutisch relevanten Einatmungsfluss/Volumenwerten | |
DE60302264T2 (de) | Medikamentenverabreichungssystem mit Regelschleife | |
DE69531835T2 (de) | Absperrvorrichtung zur geregelten abgabe einer arznei aus einer patientenaktivierten austragevorrichtung | |
DE69433380T2 (de) | Systeme zur interpulmonaren verabreichung von wässrigen lösungen | |
EP1881858B1 (de) | Vorrichtung zur steuerung einer mehrzahl von infusionspumpen | |
EP1258264B1 (de) | Vorrichtung zum Verabreichen von Aerosolen | |
DE60020695T2 (de) | Medikamentenspender | |
DE69534450T2 (de) | Vorrichtung zur vernebelung von betäubungsmitteln | |
DE60220378T2 (de) | Gerät zur Verabreichung einer muskelrelaxierenden Arznei an Patienten | |
DE60127534T2 (de) | Gehäuse für einen inhalator | |
US20060079831A1 (en) | Quantitative chronological medical infusion device | |
CN103917265A (zh) | 鼻药递送装置 | |
Musk et al. | Target‐controlled infusion of propofol in dogs–evaluation of four targets for induction of anaesthesia | |
Smolensky et al. | Clinical chronobiology and chronotherapeutics with applications to asthma | |
US20220409127A1 (en) | Remote aggregation of data for drug administration devices | |
US20180369514A1 (en) | Metered Dose Inhaler | |
EP4034205A1 (de) | Mit einer arzneimittelverabreichung verbundene messparameter und arzneimittelverabreichungsvorrichtungen damit | |
AU2020356531A1 (en) | Drug administration system configured to determine a drug dosing scheme | |
EP1542644B1 (de) | Medikament-dosimeter-kombipackung | |
DE3028808A1 (de) | Verfahren und arzneimittelverpackung zur nachtraeglichen bestimmung der oeffnungszeitpunkte einer arzneimittelverpackung | |
CN107693484A (zh) | 一种利福平凝胶及其制备方法 | |
Raju et al. | Accuracy and precision of intraocular injection volume | |
WO2005107836A1 (en) | Quantitative chronological medical infusion device | |
DE60120498T2 (de) | Verfahren und vorrichtung zum erleichtern der kombinierten anwendung von aerosolen und oralen behandlungen für diabetes mellites | |
EP2919740B1 (de) | Vorrichtung und verfahren zur herstellung, dosierung und verpackung von arzneimitteln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050322 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GREB, WOLFGANG Inventor name: SCHREIER, HANS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE ES FR GB IT TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REF | Corresponds to: |
Ref document number: 50308742 Country of ref document: DE Date of ref document: 20080117 Kind code of ref document: P |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20080117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080316 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20080908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071205 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 50308742 Country of ref document: DE Representative=s name: BUNGARTZ CHRISTOPHERSEN PARTNERSCHAFT MBB PATE, DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20150922 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20150923 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20151001 Year of fee payment: 13 Ref country code: IT Payment date: 20150925 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 50308742 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20160924 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20170531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170401 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160930 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160924 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160924 |